DK4225351T1 - Sammensætning og fremgangsmåde til behandling af kræft under anvendelse af en vaccine som en første terapeutisk aktiv ingrediens i kombination med en anden aktiv ingrediens - Google Patents

Sammensætning og fremgangsmåde til behandling af kræft under anvendelse af en vaccine som en første terapeutisk aktiv ingrediens i kombination med en anden aktiv ingrediens Download PDF

Info

Publication number
DK4225351T1
DK4225351T1 DK21880926.7T DK21880926T DK4225351T1 DK 4225351 T1 DK4225351 T1 DK 4225351T1 DK 21880926 T DK21880926 T DK 21880926T DK 4225351 T1 DK4225351 T1 DK 4225351T1
Authority
DK
Denmark
Prior art keywords
active ingredient
vaccine
cancer
treatment
composition
Prior art date
Application number
DK21880926.7T
Other languages
Danish (da)
English (en)
Inventor
Tim Ioannides
Evangelos V Badiavas
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/068,087 external-priority patent/US11813329B2/en
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of DK4225351T1 publication Critical patent/DK4225351T1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21880926.7T 2020-10-12 2021-10-12 Sammensætning og fremgangsmåde til behandling af kræft under anvendelse af en vaccine som en første terapeutisk aktiv ingrediens i kombination med en anden aktiv ingrediens DK4225351T1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/068,087 US11813329B2 (en) 2014-10-24 2020-10-12 Method and composition for treating cancer or skin lesion using a vaccine
PCT/US2021/054622 WO2022081604A1 (en) 2020-10-12 2021-10-12 Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient

Publications (1)

Publication Number Publication Date
DK4225351T1 true DK4225351T1 (da) 2023-10-23

Family

ID=81208565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21880926.7T DK4225351T1 (da) 2020-10-12 2021-10-12 Sammensætning og fremgangsmåde til behandling af kræft under anvendelse af en vaccine som en første terapeutisk aktiv ingrediens i kombination med en anden aktiv ingrediens

Country Status (16)

Country Link
EP (1) EP4225351A1 (ko)
JP (1) JP2023546073A (ko)
KR (1) KR20230117106A (ko)
AU (1) AU2021360676A1 (ko)
CA (1) CA3195478A1 (ko)
CO (1) CO2023006083A2 (ko)
CY (1) CY20232200001T2 (ko)
DE (1) DE21880926T1 (ko)
DK (1) DK4225351T1 (ko)
ES (1) ES2962700T1 (ko)
FI (1) FI4225351T1 (ko)
HU (1) HUE21880926T1 (ko)
IL (1) IL302098A (ko)
MX (1) MX2023004285A (ko)
PL (1) PL4225351T1 (ko)
WO (1) WO2022081604A1 (ko)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EA201891965A1 (ru) * 2016-04-01 2019-04-30 Кайт Фарма, Инк. Химерные рецепторы антигенов и т-клеточные рецепторы и способы их применения
WO2017177137A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions

Also Published As

Publication number Publication date
IL302098A (en) 2023-06-01
JP2023546073A (ja) 2023-11-01
HUE21880926T1 (hu) 2024-04-28
ES2962700T1 (es) 2024-03-20
KR20230117106A (ko) 2023-08-07
FI4225351T1 (fi) 2023-10-20
WO2022081604A1 (en) 2022-04-21
CY20232200001T2 (el) 2024-02-16
MX2023004285A (es) 2023-06-19
PL4225351T1 (pl) 2023-12-11
DE21880926T1 (de) 2024-01-11
CA3195478A1 (en) 2022-04-21
AU2021360676A1 (en) 2023-06-15
CO2023006083A2 (es) 2023-08-18
EP4225351A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
EP4097122A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
BR112018013245A2 (pt) método e aparelho para administração óxido nítrico com drogas suplementares
IL262213A (en) Device and a method for controlled administering of a therapeutic composition to a patient
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
CY1119597T1 (el) Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CY1115245T1 (el) Φαρμακευτικη συνθεση που συνδυαζει διαφορους φλεβοτονικους και αγγειοπροστατευτικους παραγοντες για τη θεραπεια χρονιας φλεβικης ανεπαρκειας
DK3886894T3 (da) Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
PE20211818A1 (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
DK4225351T1 (da) Sammensætning og fremgangsmåde til behandling af kræft under anvendelse af en vaccine som en første terapeutisk aktiv ingrediens i kombination med en anden aktiv ingrediens
GB2604737B (en) Escape profiling for therapeutic and vaccine development
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
AR053154A1 (es) Metodo de tratamiento y combinacion de roflumilast y un inhibidor de integrina
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2022000663A (es) Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
EP4054695A4 (en) SYSTEM AND MINIATURE DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC CONSTITUENT AT A TREATMENT SITE IN A PATIENT
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
BR112017024073A2 (pt) métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase